Cargando…

Marketing in Heterozygous Advantage

As the rapidly advancing possibilities of biotechnology have outstripped the adaptive capacity of current legal and ethical institutions, a vigorous debate has arisen that considers the boundaries of appropriate use of this technology, particularly when applied to humans. This article examines ethic...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Gregory Todd, Hagtvedt, Reidar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087662/
https://www.ncbi.nlm.nih.gov/pubmed/32214562
http://dx.doi.org/10.1007/s10551-006-9301-4
_version_ 1783509377450246144
author Jones, Gregory Todd
Hagtvedt, Reidar
author_facet Jones, Gregory Todd
Hagtvedt, Reidar
author_sort Jones, Gregory Todd
collection PubMed
description As the rapidly advancing possibilities of biotechnology have outstripped the adaptive capacity of current legal and ethical institutions, a vigorous debate has arisen that considers the boundaries of appropriate use of this technology, particularly when applied to humans. This article examines ethical concerns surrounding the development of markets in a particular form of human genetic engineering in which heterozygotes are fitter than both homozygotes, a condition known as heterozygous advantage. To begin, we present a generalized model of the condition, illuminated by the application to sickle-cell anemia. Next, we propose a typology of related markets, some of which are currently functioning with available products and services, and others that are widely viewed as imminent. We suggest the manner in which perverse incentives may arise for firms that market genetic intervention in circumstances where heterozygous advantage is possible. Finally, we propose that this misalignment of incentives with social welfare has arisen from both ill-conceived market intervention where markets are capable of achieving efficient outcomes and the lack of market intervention where markets have failed. We offer specific legal and regulatory approaches for reform.
format Online
Article
Text
id pubmed-7087662
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-70876622020-03-23 Marketing in Heterozygous Advantage Jones, Gregory Todd Hagtvedt, Reidar J Bus Ethics Article As the rapidly advancing possibilities of biotechnology have outstripped the adaptive capacity of current legal and ethical institutions, a vigorous debate has arisen that considers the boundaries of appropriate use of this technology, particularly when applied to humans. This article examines ethical concerns surrounding the development of markets in a particular form of human genetic engineering in which heterozygotes are fitter than both homozygotes, a condition known as heterozygous advantage. To begin, we present a generalized model of the condition, illuminated by the application to sickle-cell anemia. Next, we propose a typology of related markets, some of which are currently functioning with available products and services, and others that are widely viewed as imminent. We suggest the manner in which perverse incentives may arise for firms that market genetic intervention in circumstances where heterozygous advantage is possible. Finally, we propose that this misalignment of incentives with social welfare has arisen from both ill-conceived market intervention where markets are capable of achieving efficient outcomes and the lack of market intervention where markets have failed. We offer specific legal and regulatory approaches for reform. Springer Netherlands 2007-02-15 2008 /pmc/articles/PMC7087662/ /pubmed/32214562 http://dx.doi.org/10.1007/s10551-006-9301-4 Text en © Springer Science+Business Media B.V. 2007 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Jones, Gregory Todd
Hagtvedt, Reidar
Marketing in Heterozygous Advantage
title Marketing in Heterozygous Advantage
title_full Marketing in Heterozygous Advantage
title_fullStr Marketing in Heterozygous Advantage
title_full_unstemmed Marketing in Heterozygous Advantage
title_short Marketing in Heterozygous Advantage
title_sort marketing in heterozygous advantage
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087662/
https://www.ncbi.nlm.nih.gov/pubmed/32214562
http://dx.doi.org/10.1007/s10551-006-9301-4
work_keys_str_mv AT jonesgregorytodd marketinginheterozygousadvantage
AT hagtvedtreidar marketinginheterozygousadvantage